‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly Pivots Into Drug Development

{
  "signal_id": "01336acf-29c0-1b7d-7f37-c3e313a7e29e",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-27T23:30:18+00:00",
  "company": {
    "name": "OpenEvidence",
    "domain": "openevidence.com"
  },
  "data": {
    "url": "https://en.wowtale.net/2026/09/28/235252/",
    "title": "‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly Pivots Into Drug Development - Wowtale",
    "excerpt": "The market for AI-powered clinical search is heating up. Publicly traded Doximity told investors its AI Scribe user base nearly tripled in a single quarter, while Abridge took a strategic equity investment from Eli Lilly and is expanding into clinical-trial patient recruitment. Even OpenEvidence , the company that built the “ChatGPT for doctors” category, isn’t immune to that pressure. OpenEvidence raised another $250 million, Forbes reported . The company itself never put out a press release. What stands out is how quietly it landed: unlike January’s Series D - a $12 billion valuation announced with a CNBC appearance for the CEO - this one surfaced as a single sentence buried inside a Forbes story about a hospital partnership. CEO Daniel Nadler told Forbes that OpenEvidence is moving into developing its own cancer drugs, with a first candidate entering clinical trials before year-end and three to five more next year, starting with rare cancers. Rather than go head-to-head with Eli Lilly or Pfizer on large trials, Nadler said the company is targeting “the stuff that they are not doing, and maybe can’t do” - the bet being that reaching most of America’s physicians makes it far easier to find the handful of patients a rare-disease trial needs. The partnership announced the same day is the first building block. MSK and OpenEvidence said they’re integrating OpenEvidence into MSK’s...",
    "product": "Darwin",
    "summary": "OpenEvidence unveiled its new Darwin model family, with the Darwin model becoming the first AI to achieve a perfect score on the MedQA medical AI benchmark.",
    "planning": false,
    "image_url": "https://cdn.wowtale.net/wp-content/uploads/sites/2/2026/09/open-evidence-logo-1024x538.jpg",
    "confidence": 1,
    "product_data": {
      "name": "Darwin",
      "full_text": "its Darwin model",
      "fuzzy_match": false,
      "release_type": "model"
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "future_tech",
      "medical",
      "data"
    ],
    "published_at": "2026-09-27T23:30:18Z",
    "article_sentence": "The new model family OpenEvidence unveiled earlier this month points the same direction."
  }
}

curl https://signals.autobound.ai/v1/signals/01336acf-29c0-1b7d-7f37-c3e313a7e29e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"openevidence.com","limit":20}'